Patents by Inventor William Vainchenker
William Vainchenker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11732303Abstract: The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that proposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF), secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL, and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis, a secondary MDS or an AML.Type: GrantFiled: June 24, 2016Date of Patent: August 22, 2023Assignee: Institut Gustave-RoussyInventors: Christine Bellane-Chantelot, Isabelle Plo, William Vainchenker, Cécile Saint-Martin, Antonio D Di Stefano, Joseph Saliba
-
Publication number: 20220042016Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: September 29, 2021Publication date: February 10, 2022Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUDInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 11203788Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.Type: GrantFiled: April 8, 2020Date of Patent: December 21, 2021Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PIERRE ET MARIE CURIE, UNIVERSITE PARIS-SUDInventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
-
Patent number: 11162100Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: January 6, 2020Date of Patent: November 2, 2021Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUDInventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20200255912Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.Type: ApplicationFiled: April 8, 2020Publication date: August 13, 2020Inventors: Franck VIGUIE, Olivier BERNARD, Michaela FONTENAY, Christian BASTARD, Francois DELHOMMEAU, William VAINCHENKER
-
Publication number: 20200239961Abstract: The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that predisposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF) secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis a secondary MDS or an AML.Type: ApplicationFiled: June 24, 2016Publication date: July 30, 2020Applicant: Institut Gustave-RoussyInventors: CHRISTINE BELLANNE-CHANTELOT, Isabelle PLO, William VAINCHENKER, Cécile SAINT-MARTIN, Antonio DI STEFANO, Joseph SALIBA
-
Patent number: 10662482Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.Type: GrantFiled: June 8, 2016Date of Patent: May 26, 2020Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PARIS DESCARTES, UNIVERSITY PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS-SUDInventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
-
Publication number: 20200140863Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: January 6, 2020Publication date: May 7, 2020Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUDInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 10563200Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: May 29, 2019Date of Patent: February 18, 2020Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES—ST QUENTIN EN YVELINES, UNIVERSITE PARIS—SUDInventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20190323007Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: May 29, 2019Publication date: October 24, 2019Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Rescherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris-SudInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 10364430Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: January 27, 2014Date of Patent: July 30, 2019Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES—ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUDInventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20160319370Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.Type: ApplicationFiled: June 8, 2016Publication date: November 3, 2016Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS-SUDInventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
-
Patent number: 9389233Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.Type: GrantFiled: June 12, 2009Date of Patent: July 12, 2016Assignees: Institute National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave-Roussy, Assistance Publique-Hopitaux de Paris, Centre Henri Becquerel, Universite Paris Descartes, Universite Pierre et Marie Curie (PARIS 6), Universite Paris-SudInventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
-
Patent number: 9297046Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.Type: GrantFiled: March 21, 2012Date of Patent: March 29, 2016Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE, UNIVERSITE PARIS-SUD 11Inventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
-
Publication number: 20150232932Abstract: An in vitro method for diagnosing thrombocytopenia in a subject, the method includes the step of assessing the ANKRD26 platelet expression in a biological sample from the subject, wherein a ANKRD26 platelet expression is indicative of a thrombocytopenia. Also described is a kit for diagnosing a thrombocytopenia in a subject, which includes at least one ANKRD26 nucleic acid probe or oligonucleotide or antibody for assessing the ANKRD26 platelet expression in a biological sample from the subject.Type: ApplicationFiled: September 17, 2013Publication date: August 20, 2015Applicant: INSTITUT GUSTAVE ROUSSYInventors: Dominique Bluteau, Remi Favier, Hana Raslova, William Vainchenker
-
Publication number: 20150051263Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: January 27, 2014Publication date: February 19, 2015Inventors: William VAINCHENKER, Valerie UGO, Chloe JAMES, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 8852931Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: February 15, 2013Date of Patent: October 7, 2014Assignees: Assitance Publique—Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Gustave-Roussy, Universite de Versailles—St Quentin en Yvelines, Universite Paris-SudInventors: William Vainchenker, Valérie Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20140249204Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: January 27, 2014Publication date: September 4, 2014Applicants: Institut Gustave-Roussy, Institut National De La Sante Et De La Rechereche Scientifique (Inserm), Universite Paris-Sud, Universite De Versailles - St Quentin En Yvelines, Assistance Publique-Hopitaux De ParisInventors: William Vainchenker, Valeria Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall
-
Patent number: 8637235Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: September 19, 2008Date of Patent: January 28, 2014Assignees: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Scientifique (CNRS), Assistance Publique—Hopitaux de Paris, Universite de Versailles—St Quentin en Yvelines, Universite Paris—SUDInventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20130344494Abstract: A method of diagnosing a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation in a subject, which includes the step of i) determining the platelets' myosin non-muscle heavy chain 10 (MYH10) expression level in a biological sample from the subject, and wherein a detectable platelets' MYH10 expression level is indicative of a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation, and to a kit for diagnosing a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation in a subject including i) at least one antibody for determining the platelet MYH10 expression level in a biological sample from the subject, which can be used in a such a method.Type: ApplicationFiled: February 23, 2012Publication date: December 26, 2013Inventors: Dominique Bluteau, Yunchua Chang-Marchand, Rémi Favier, Larissa Lordier, Hana Raslova, William Vainchenker